Freestone Grove Partners’s Supernus Pharmaceuticals SUPN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-316,398
Closed -$14.7M – 1082
2026
Q2
$14.7M Sell
316,398
-324,921
-51% -$15.6M 0.09% 246
2026
Q1
$33.1M Buy
641,319
+445,001
+227% +$22.7M 0.23% 147
2025
Q4
$9.8M Buy
+196,318
New +$9.5M 0.07% 294

Other funds holding SUPN

Freestone Grove Partners's SUPN Position: Q3 2026 in Review

Freestone Grove Partners sold out of Supernus Pharmaceuticals (SUPN) in Q3 2026, closing a stake of 316,398 shares — an estimated $14.7M sold.

Freestone Grove Partners first reported a position in SUPN in Q4 2025 and held it in 3 quarters. The position peaked at $33.1M in Q1 2026. 294 funds tracked by Wall St. Rank hold SUPN as of Q3 2026.

  • Freestone Grove Partners reported no remaining Supernus Pharmaceuticals position as of Q3 2026 after selling out during the quarter.
  • Freestone Grove Partners sold 316,398 Supernus Pharmaceuticals shares in Q3 2026, an estimated $14.7M.
  • Freestone Grove Partners first reported a position in Supernus Pharmaceuticals in Q4 2025 and held it in 3 quarters.
  • Freestone Grove Partners's Supernus Pharmaceuticals position peaked at $33.1M in Q1 2026.
  • 294 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q3 2026.

Based on Freestone Grove Partners's 13F filing for Q3 2026, filed 16 Nov 2026.